SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (4561)6/25/1998 2:03:00 PM
From: Andreas Helke  Read Replies (1) | Respond to of 6136
 
If endostatin works as well in humans as it does in mice it will be the most serious competition to all other available and future cancer drugs. Those other drugs may still have their chance in combination therapy.

Endostatin will not be an approved product in two years but we may know by then how well it works. If it does not work particulary well it will probably need more time to figure out if it is a useful drug. But if it works as well in humans as it does in mice it could be the first cancer drug that demonstrates efficacy in a phase I trial.

Andreas



To: scaram(o)uche who wrote (4561)6/27/1998 7:31:00 AM
From: billkirn  Read Replies (1) | Respond to of 6136
 
>> *If* 3340 works, and *if* an agent that inhibits the differentiation or proliferation of
endothelial cells works, I do not believe that they will be competitive products. >>

Do you know what companies are working on the endothelial cell inhibitor...is that AG2034??
Bill


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News